u/GeoLogic23

• Gross Revenue: $145.1 million (+32% year-over-year).
• Net Revenue: $105.8 million (+49% year-over-year).
• Adjusted EBITDA^(1)****: $13.4 million (+136% year-over-year).
• #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages^(2).
• Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During the quarter, Sanity continued to execute on its European growth strategy, advancing preparations for an additional Swiss recreational pilot project, progressing its entry into Poland, launching branded products in the UK through new strategic partnerships, establishing a significant new Swiss medical partnership, and recording its first meaningful medical cannabis sales in Switzerland.

Net revenue growth of 22% in Canada medical cannabis, 10% in Canada adult-use cannabis, 10% in international markets cannabis and 6% in Storz & Bickel

Adjusted gross margin^(1) improves to 31% in Q1 FY2027 from 25% in Q1 FY2026

Adjusted EBITDA^(2) loss narrows by 59% year-over-year

For decades, cannabis brands competed on one metric: potency. More THC meant a better product, at least for experienced consumers chasing a stronger high. But in today's maturing legal market, some of the most successful companies are taking the opposite approach, betting on precision instead of potency to win over adults who don't regularly consume cannabis.

Low-dose beverages, gummies and other precisely dosed products represent a real opportunity to convert this untapped, cannabis-curious audience.

Q2 Revenue of $42.4 million and Net Income of $2.9 million

Sustains Consecutive Quarters of Adjusted EBITDA Profitability

Organically achieved record net revenue, gross profit, and Adjusted EBITDA while reducing share count

Net revenue in Q2 2026 increased by 51% year-over-year on an organic, constant-currency basis

Delivered record net revenue in Canada, with Spinach^(®) maintaining #1 market share in vapes and edibles^(1)

Tenth consecutive quarter of record net revenue in Israel, where PEACE NATURALS^(®) continues to be the #1 cannabis brand^(2)

Generated record net revenue outside Canada and Israel, led by strong demand for PEACE NATURALS^(®) in Germany

Repurchased 12.3 million shares in the first half of 2026

• Delivers Net Revenue of $67.6 million, including a 17% YoY Increase in International Medical Cannabis Net Revenue
• Safari Flower Company Receives Three-Year EU-GMP Certification, Strengthens Ability to Supply Growing, High-Margin International Medical Cannabis Markets
• Maintains Strong Balance Sheet with $149.1 million of Cash, Cash Equivalents*^(2)*and Short-Term Investments with no Debt

Highlights for the second quarter ended June 30, 2026:

• Revenue from continuing operations of $23.0 million, up 73% from $13.3 million in the prior quarter.
• Cash increased to $41.9 million driven by cash flow from operations of $8.7 million.
• Net income of $1.2 million.
• Adjusted EBITDA of $6.4 million compared to approximately breakeven in the prior quarter.
• At quarter end, the Company had approximately 2.2 million shares outstanding, as well as 11.0 million warrants outstanding and 3.0 million shares issuable upon conversion of outstanding convertible notes (excluding shares issuable upon conversion from accrued interest).